|
MechanismVoltage-gated sodium channels blockers |
|
|
|
|
Drug Highest PhaseApproved |
First Approval Ctry. / Loc.US |
First Approval Date14 Dec 2017 |
Target- |
MechanismNitric oxide donors |
|
|
|
|
Drug Highest PhaseApproved |
First Approval Ctry. / Loc.US |
First Approval Date30 Dec 1991 |
100 Clinical Results associated with Omnivium Pharmaceuticals LLC
0 Patents (Medical) associated with Omnivium Pharmaceuticals LLC
100 Deals associated with Omnivium Pharmaceuticals LLC
100 Translational Medicine associated with Omnivium Pharmaceuticals LLC